Cargando…

Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase

BACKGROUND: The biguanides are a family of drugs with diverse clinical applications. Metformin, a widely used anti-hyperglycemic biguanide, suppresses mitochondrial respiration by inhibiting respiratory complex I. Phenformin, a related anti-hyperglycemic biguanide, also inhibits respiration, but pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Bridges, Hannah R., Sirviö, Ville A., Agip, Ahmed-Noor A., Hirst, Judy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977651/
https://www.ncbi.nlm.nih.gov/pubmed/27506389
http://dx.doi.org/10.1186/s12915-016-0287-9
_version_ 1782447069136420864
author Bridges, Hannah R.
Sirviö, Ville A.
Agip, Ahmed-Noor A.
Hirst, Judy
author_facet Bridges, Hannah R.
Sirviö, Ville A.
Agip, Ahmed-Noor A.
Hirst, Judy
author_sort Bridges, Hannah R.
collection PubMed
description BACKGROUND: The biguanides are a family of drugs with diverse clinical applications. Metformin, a widely used anti-hyperglycemic biguanide, suppresses mitochondrial respiration by inhibiting respiratory complex I. Phenformin, a related anti-hyperglycemic biguanide, also inhibits respiration, but proguanil, which is widely used for the prevention of malaria, does not. The molecular structures of phenformin and proguanil are closely related and both inhibit isolated complex I. Proguanil does not inhibit respiration in cells and mitochondria because it is unable to access complex I. The molecular features that determine which biguanides accumulate in mitochondria, enabling them to inhibit complex I in vivo, are not known. RESULTS: Here, a family of seven biguanides are used to reveal the molecular features that determine why phenformin enters mitochondria and inhibits respiration whereas proguanil does not. All seven biguanides inhibit isolated complex I, but only four of them inhibit respiration in cells and mitochondria. Direct conjugation of a phenyl group and bis-substitution of the biguanide moiety prevent uptake into mitochondria, irrespective of the compound hydrophobicity. This high selectivity suggests that biguanide uptake into mitochondria is protein mediated, and is not by passive diffusion. Only those biguanides that enter mitochondria and inhibit complex I activate AMP kinase, strengthening links between complex I and the downstream effects of biguanide treatments. CONCLUSIONS: Biguanides inhibit mitochondrial complex I, but specific molecular features control the uptake of substituted biguanides into mitochondria, so only some biguanides inhibit mitochondrial respiration in vivo. Biguanides with restricted intracellular access may be used to determine physiologically relevant targets of biguanide action, and for the rational design of substituted biguanides for diverse clinical applications. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12915-016-0287-9) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4977651
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49776512016-08-10 Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase Bridges, Hannah R. Sirviö, Ville A. Agip, Ahmed-Noor A. Hirst, Judy BMC Biol Research Article BACKGROUND: The biguanides are a family of drugs with diverse clinical applications. Metformin, a widely used anti-hyperglycemic biguanide, suppresses mitochondrial respiration by inhibiting respiratory complex I. Phenformin, a related anti-hyperglycemic biguanide, also inhibits respiration, but proguanil, which is widely used for the prevention of malaria, does not. The molecular structures of phenformin and proguanil are closely related and both inhibit isolated complex I. Proguanil does not inhibit respiration in cells and mitochondria because it is unable to access complex I. The molecular features that determine which biguanides accumulate in mitochondria, enabling them to inhibit complex I in vivo, are not known. RESULTS: Here, a family of seven biguanides are used to reveal the molecular features that determine why phenformin enters mitochondria and inhibits respiration whereas proguanil does not. All seven biguanides inhibit isolated complex I, but only four of them inhibit respiration in cells and mitochondria. Direct conjugation of a phenyl group and bis-substitution of the biguanide moiety prevent uptake into mitochondria, irrespective of the compound hydrophobicity. This high selectivity suggests that biguanide uptake into mitochondria is protein mediated, and is not by passive diffusion. Only those biguanides that enter mitochondria and inhibit complex I activate AMP kinase, strengthening links between complex I and the downstream effects of biguanide treatments. CONCLUSIONS: Biguanides inhibit mitochondrial complex I, but specific molecular features control the uptake of substituted biguanides into mitochondria, so only some biguanides inhibit mitochondrial respiration in vivo. Biguanides with restricted intracellular access may be used to determine physiologically relevant targets of biguanide action, and for the rational design of substituted biguanides for diverse clinical applications. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12915-016-0287-9) contains supplementary material, which is available to authorized users. BioMed Central 2016-08-09 /pmc/articles/PMC4977651/ /pubmed/27506389 http://dx.doi.org/10.1186/s12915-016-0287-9 Text en © Bridges et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Bridges, Hannah R.
Sirviö, Ville A.
Agip, Ahmed-Noor A.
Hirst, Judy
Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase
title Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase
title_full Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase
title_fullStr Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase
title_full_unstemmed Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase
title_short Molecular features of biguanides required for targeting of mitochondrial respiratory complex I and activation of AMP-kinase
title_sort molecular features of biguanides required for targeting of mitochondrial respiratory complex i and activation of amp-kinase
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4977651/
https://www.ncbi.nlm.nih.gov/pubmed/27506389
http://dx.doi.org/10.1186/s12915-016-0287-9
work_keys_str_mv AT bridgeshannahr molecularfeaturesofbiguanidesrequiredfortargetingofmitochondrialrespiratorycomplexiandactivationofampkinase
AT sirviovillea molecularfeaturesofbiguanidesrequiredfortargetingofmitochondrialrespiratorycomplexiandactivationofampkinase
AT agipahmednoora molecularfeaturesofbiguanidesrequiredfortargetingofmitochondrialrespiratorycomplexiandactivationofampkinase
AT hirstjudy molecularfeaturesofbiguanidesrequiredfortargetingofmitochondrialrespiratorycomplexiandactivationofampkinase